Accera, Inc.
Records under this name other than patents Accera, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,105,338 | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,125,881 | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,105,809 | Enzymatic synthesis of acetoacetate esters and derivatives Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,175,345 | Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,445,535 | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II Formerly held Term ended Term ended Mar 4, 2024 · From the USPTO record | Term ended | Term ended Mar 4, 2024 | From the USPTO record |
| US 8,124,589 | Use of ketogenic compounds for treatment of age-associated memory impairment Formerly held Term ended Term ended Jul 14, 2021 · From the USPTO record | Term ended | Term ended Jul 14, 2021 | From the USPTO record |
| US 6,835,750 | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II Formerly held Term ended Term ended May 20, 2021 · From the USPTO record | Term ended | Term ended May 20, 2021 | From the USPTO record |
| US 8,426,468 | Use of medium chain triglycerides for the treatment and prevention of alzheimer'S disease and other diseases resulting from reduced neuronal metabolism Formerly held Term ended Ended no later than May 1, 2021 · From the USPTO record | Term ended | Ended no later than May 1, 2021 | From the USPTO record |
| US 8,748,400 | Use of ketogenic compounds for treatment of age-associated memory impairment Formerly held Term ended Ended no later than May 1, 2021 · From the USPTO record | Term ended | Ended no later than May 1, 2021 | From the USPTO record |
| US 9,603,823 | Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II Formerly held Term ended Ended no later than May 1, 2021 · From the USPTO record | Term ended | Ended no later than May 1, 2021 | From the USPTO record |